for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aethlon Medical, Inc.

AEMD.OQ

Latest Trade

4.85USD

Change

0.24(+5.21%)

Volume

7,385

Today's Range

4.55

 - 

5.02

52 Week Range

3.08

 - 

26.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.61
Open
4.55
Volume
7,385
3M AVG Volume
0.43
Today's High
5.02
Today's Low
4.55
52 Week High
26.10
52 Week Low
3.08
Shares Out (MIL)
1.33
Market Cap (MIL)
6.45
Forward P/E
-1.20
Dividend (Yield %)
--

Next Event

Aethlon Medical Inc at Biotechnology Industry Organization (BIO) Investor Forum Conference

Latest Developments

More

Aethlon Announces Reverse Stock Split

Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

Aethlon Medical Says National Cancer Institute Awarded Co SBIR Phase 2 Contract For Topic 359

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aethlon Medical, Inc.

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

Industry

Biotechnology & Drugs

Contact Info

9635 Granite Ridge Dr Ste 100

+1.858.4597800

https://www.aethlonmedical.com/

Executive Leadership

Charles J Fisher

Independent Chairman and Director

Timothy C. Rodell

Interim Chief Executive Officer, Director

James B. Frakes

Chief Financial Officer, Senior Vice President - Finance, IR Contact Officer

Edward G. Broenniman

Independent Director

Guy F. Cipriani

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.460

2019

-0.340

2020(E)

-4.050
Price To Earnings (TTM)
--
Price To Sales (TTM)
58.61
Price To Book (MRQ)
5.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
77.95
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-194.08
Return on Equity (TTM)
-152.01

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up